Table 1

Baseline characteristics of SLE patients in this study (n=60)

CharacteristicsIL-2 (n=30)Placebo (n=30)P value
Age, year, mean±SD31.58±9.2529.83±9.720.474
Female/male27/329/10.612
Weight, kg, mean±SD54.81±8.3358.69±8.870.117
Height, cm, mean±SD162.23±6.81162.67±5.410.743
Area, m2, mean±SD1.57±0.1401.62±0.130.708
Duration, months, mean±SD66.7±57.463.6±59.90.652
SLEDAI, median (range)12 (8–27)11 (8–22)0.351
BILAG, median (range)10 (8–13)10.5 (8–13.75)0.372
≥1 BLIAG A or 2B score (%)21 (70)21 (70)1.000
PGA, median (range)2.3 (1.55–2.75)2.2 (1–2.3)0.446
Medications
 Prednisone dose, mg/day, median (range)12.5 (0–50)15 (5–50)0.331
 Hydroxychloroquine29 (96.67)28 (93.33)1.000
 Cyclophosphamide4 (13.33)0 (0)0.112
 Azathioprine1 (3.33)4 (13.33)0.352
 Cyclosporine0 (0)5 (16.67)0.052
 Mycophenolate mofetil9 (30.00)8 (26.67)1.000
 Tacrolimus1 (3.33)1 (3.33)1.000
 Leflunomide3 (10.00)1 (3.33)0.611
 Thalidomide1 (3.33)0 (0)1.000
 Methotrexate1 (3.33)1 (3.33)1.000
  • Baseline information was collected at the time the systemic lupus erythematosus (SLE) patients entered the double-blind period of the study.

  • For a continuous variable, median (range) and mean±SD, for a categorical variable, count (percentage).

  • Area, body surface area; BILAG, British Isles Lupus Assessment Group; PGA, physician's global assessment; SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index.